DLC Antibodies

Santa Cruz Biotechnology provides a broad selection of DLC Antibodies for studying the Deleted in Liver Cancer (DLC) protein family. DLC Antibodies are compatible with multiple research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). DLC proteins regulate cell growth and maintain cellular integrity, making them significant targets in cancer biology research, particularly in liver cancer studies. As tumor suppressors, DLC proteins are essential for understanding cancer development and progression. Researchers worldwide utilize DLC monoclonal antibodies to investigate cellular signaling pathways and molecular mechanisms involved in cancer. Advanced detection methods with conjugates like horseradish peroxidase (HRP), phycoerythrin (PE), and fluorescein isothiocyanate (FITC) enable precise visualization of DLC proteins in various experimental setups. Understanding DLC protein expression patterns helps identify potential therapeutic targets and biomarkers. Santa Cruz Biotechnology monoclonal antibodies for DLC proteins support researchers in advancing cancer research and developing innovative treatment strategies.